

Prime Recipient

Reporting Information

Award Type*	Award Number*	Final Report*
Grant	1R21DA023841-01A1	N

Award Recipient Information

Recipient DUNS Number*	Recipient Account Number	Recipient Congressional District*
073157737	2714A-12714	11

Award Information

Funding Agency Code*	Awarding Agency Code*	Award Date*
7529	7529	07/16/2009
Amount of Award*	CFDA Number*	
\$312,151.00	93.701	
Program Source (TAS)*	Sub Account Number for Program Source (TAS)	
75-0908		
Total Number of Sub Awards to Individuals*	Total Amount of Sub Awards to Individuals*	
0.00	\$0.00	
Total Number of Payments to Vendors less than \$25,000/award*	Total Amount of Payments to Vendors less than \$25,000/award*	
90.00	\$25,894.81	
Total Number of Sub Awards less than \$25,000/award*	Total Amount of Sub Awards less than \$25,000/award*	
0.00	\$0.00	
Award Description*		

Need Help Finding Award Information?

Browse the Full Listings by using the drop-down lists.

Agency Drop-Down List: 7529 - National Institutes of Health

Program Source (TAS) Drop-Down List: 75-0908-HHS-National Institutes of Health-National Institute on Drug Abuse

Know the code and want to check the name?
Search by Code

Enter Agency Code: 7529

Agency Name: National Institutes of Health

Enter Program Source (TAS) Code: 75-0908

Program Source (TAS) Name: HHS-National Institutes of Health-National Institute on Drug Abuse

Know the name and want to find the code?
Search by Name

Enter Agency Name: National Institutes of Health

Agency Code: 7529

Enter Program Source (TAS) Name: HHS-National Institutes of Health-National Institute on Drug Abuse

Program Source (TAS) Code: 75-0908

The long term goal of this project is to develop therapeutics that will result in the elimination of human immunodeficiency virus. The objective of this particular application, which represents a first step toward the attainment of our long term goal, is the development of Trojan horse inhibitors (THIs) that are activated by HIV protease and serve to kill the cells in which the HIV is attempting to replicate. The specific aims of the project are to: 1. Determine the in vitro functionality of THIs, 2. Investigate the ability of the first generation THI to kill HIV infected cells and reduce virus production in tissue culture, and 3. Design the second and subsequent generations of THI. Expected outputs and outcomes: It is expected that the first generation Trojan Horse Inhibitor, THI-1, will be produced and evaluated for in vitro and in vivo activity. The second generation THI, THI-2 has been designed but not cloned. It is expected that the THI-2 will be expressed and purified. Significant deliverables will include production and evaluation of THI-1 and production of THI-2.

Number of characters entered: 1089

Project Information

Project Name or Project/Program Title*	Project Status*	Total Federal Amount ARRA Funds Received/Invoiced*
Development of Therapeutics to Eliminate HIV	Completed 50% or more	\$106,861.89

Number of Jobs*	Description of Jobs Created*
2.25	Two (2) of the jobs created by this grant are full-time positions--a Research Associate and a Research Technician. Both of the individuals hired for these positions worked full-time on the project during the fourth quarter. The project's principal investigator (PI) is also contributing effort on this project equal to 25% of his time during the fourth quarter.
Number of characters entered: 361	

Quarterly Activities/Project Description*
As defined in the award description field
Number of characters entered: 41

Activity Code (NAICS or NTEE-NPC)*			
1	H02.13.03	2	
3		4	

Need Help Finding an Activity, State, or Country Code?

Browse the Full Listing by using the drop-down list.

Activity Code Drop-Down List:	H02.13.03 - HIV/AIDS Research
--------------------------------------	-------------------------------

State Drop-Down List: TX - Texas

Recipient Highly Compensated Officers

Prime Recipient Indication of Reporting Applicability*	#	Officer Name	Officer Compensation
No	1		
	2		
	3		
	4		
	5		